2nd Quarter - Report

BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FY16 FDA Agriculture-Rural Development appropriations bill, provisions related to plasma protein therapies; H.R. 1600, Patients Access to Treatment Act.

LobbyistCovered position, as disclosed
NICOLE CARELLI —
CAROLINE SELBY New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1600 (114th)

Medicare/Medicaid MMM

Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; Medicare reimbursement methodology for DME infused drugs, generally.

LobbyistCovered position, as disclosed
NICOLE CARELLI —
CAROLINE SELBY New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2581 (114th), H.R. 2570 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.